Drug search by name

Lynparza (Olaparib Tablets) and Hematologic toxicities

Result of checking the interaction of drug Lynparza (Olaparib Tablets) and disease Hematologic toxicities for safety when used together.

Check result:

Lynparza (Olaparib Tablets) <> Hematologic toxicities

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Olaparib might cause Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), sometimes with fatal outcomes. Care should be exercised when using olaparib in patients with a history of previous cancer or bone marrow dysplasia. Do not start olaparib until patients have recovered from hematological toxicity caused by previous chemotherapy (<= Grade 1). It is recommended to monitor patients for hematological toxicities at baseline and monthly thereafter for clinically significant changes during treatment. Interrupt olaparib for prolonged hematological toxicities and monitor blood counts weekly until recovery and discontinue treatment if MDS/AML is confirmed.

Lynparza (Olaparib Tablets)

Generic Name: olaparib

Brand Name: Lynparza

Synonyms: Lynparza

What is Lynparza (Olaparib Tablets)?